Clinical Trials
12 trialsNCT07615751 2026-05-29
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07610720 2026-05-28
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05769010 2026-04-01
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Phase 2 Recruiting
NCT07335081 2026-03-24
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06770296 2025-01-13
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Recruiting
NCT05861271 2024-03-22
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06000917 2023-08-21
A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT04646759 2020-11-30
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting